Hemotune Secures CHF 14 Million for Clinical Trials

شركة هيموتون تحصل على 14 مليون فرنك سويسري للتجارب السريرية

الثلاثاء، مارس 26 مارس 2024

Hemotune’s innovative blood purification platform, HemoSystem, propels into clinical trials with a CHF 14 million Series B2 boost.

Hemotune AG, a Swiss biotech compmany, has concluded its Series B2 funding round, raising CHF 14 million, they claim in a press release. This pivotal financial injection, spearheaded by Belmondo and supported by stalwarts such as VP Venture Partners, heralds in the next stage of clinical trials for its groundbreaking HemoSystem blood purification platform.

The HemoSystem, uses nanoengineered magnetic beads. By eliminating large biomolecules directly from the bloodstream, it offers a novel avenue for multi-target treatments unattainable through conventional drug therapies.

Initially targeting the formidable challenge of sepsis-related immune suppression—a condition responsible for approximately 11 million fatalities annually and imposing a significant economic strain.

Lukas Langenegger, CEO and co-founder of Hemotune AG, expressed profound pride in the team’s milestone achievement of preclinical development and clinical trials.

Dr. Darius Madjdpour, the visionary founder at Belmondo, lauded Hemotune’s stellar performance over the past seven years, culminating in a platform technology with unparalleled potential in the medical field.

The HemoSystem’s capacity to address a spectrum of diseases and enable novel therapies was a key motivator for Belmondo’s lead role in this funding round.

Pascal Winnen, CEO of HEMEX, reaffirmed the CRO’s dedication to supporting Hemotune’s novel strategy to combat septic shock, recognising the technology’s vast potential to filter detrimental agents from the bloodstream selectively.

قصص ذات صلة

UBS Job Cuts “Not Imminent”

7 مايو 2024

UBS CEO Sergio Ermotti indicates major job cuts to follow the legal merger with Credit Suisse, targeting a streamlined...

Cartier Luxury Watches Defy Market Downtrend

8 مايو 2024

In a year where luxury watches have mostly seen a decline, Cartier stands out with a 2.4% increase in value on the...

Julius Baer Sells Kairos

3 مايو 2024

Julius Baer finalizes the sale of Kairos to Anima Holding, removing the Italian "problem subsidiary" from its portfolio....

PSP Swiss Property: Strong Earnings

7 مايو 2024

PSP Swiss Property boosts 2024 earnings, with Q1 net profits up 42% to CHF 81 million. Revised EBITDA forecast now at...

UBS Achieves $1.76 Billion Q1 Profit: Exceeding Expectations

7 مايو 2024

UBS records a $1.76 billion profit in the first quarter of 2024, surpassing expectations with advances post-Credit...

Swiss Media Empire TX Group Layoffs Staff

7 مايو 2024

TX Group, a major Swiss media conglomerate, unexpectedly lays off staff, sparking criticism as it seeks government...

Swiss Bank Valiant Reports Strong Growth in Q1 2024

3 مايو 2024

Swiss Bank Valiant sees a significant profit increase in Q1 2024, with a 28% jump in operating profit....

ابق على اتصال

جدير بالملاحظة

Is Swiss Labour Day Here To Stay? May 1st

جدير بالملاحظة

1 مايو 2024

هل سيبقى عيد العمال السويسري هنا ليبقى؟ 1 مايو

Swiss Chinese Syngenta Group: Q1 Sales Down 20%

جدير بالملاحظة

29 أبريل 2024

شركة هيموتون تحصل على 14 مليون فرنك سويسري للتجارب السريرية

شركة هيموتون تحصل على 14 مليون فرنك سويسري للتجارب السريرية

قصص ذات صلة

ابق على اتصال

جدير بالملاحظة

هل سيبقى عيد العمال السويسري هنا ليبقى؟ 1 مايو

مجموعة سينجنتا السويسرية الصينية: انخفاض مبيعات الربع الأول 20%

روابط سريعة